- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07897721
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08165784 MONOTHERAPY AND COMBINATIONS IN PARTICIPANTS WITH PIK3CA-MUTATED ADVANCED OR METASTATIC SOLID TUMORS
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients.
This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery.
All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Pfizer CT.gov Call Center
- Puhelinnumero: 1-800-718-1021
- Sähköposti: ClinicalTrials.gov_Inquiries@pfizer.com
Opiskelupaikat
-
-
-
San Juan, Puerto Rico, 00935
- Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office
-
-
-
-
Arkansas
-
Fayetteville, Arkansas, Yhdysvallat, 72703
- Highlands Oncology Group, PA
-
Rogers, Arkansas, Yhdysvallat, 72758
- Highlands Oncology Group, PA
-
Springdale, Arkansas, Yhdysvallat, 72762
- Highlands Oncology Group, PA
-
-
Michigan
-
Grand Rapids, Michigan, Yhdysvallat, 49546
- START Midwest, LLC
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- 18 years of age or older
- Advanced or metastatic cancer of the breast or colon Part 1A, IB, and 1C: HR+/HER2- advanced or metastatic breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior ADC therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastatic breast cancer with no prior systemic therapy or chemotherapy for advanced or metastatic disease
- PIK3CA mutation
- Archived tumor specimen or fresh tumor biopsy
- Measurable disease
- ECOG performance status 0 or 1
Exclusion Criteria:
- Active or clinically significant dermatologic conditions
- Active malignancy within 3 years prior to enrollment
- Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
- Major surgery or radiation therapy within 3 weeks prior to study entry
- Prior irradiation to >25% of the bone marrow
- Active or history of pneumonitis/interstitial lung disease requiring corticosteroids
- Unmanageable ascites
- Prior treatment with PI3K/AKT/mTOR pathway inhibitors may be permitted in certain study cohorts and excluded in others, as specified by the study protocol.
- Renal impairment
- Hepatic dysfunction
- Hematologic abnormalities
- Uncontrolled diabetes
- Cardiac abnormalities
- Active or history of clinically significant GI or inflammatory GI disease
- Other unacceptable abnormalities or prohibited therapies as defined by protocol
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Part 1 Dose Escalation Cohort 1A
PF-08165784 monotherapy dose escalation for participants with advanced or metastatic BC at different doses of the study drug |
Taken by mouth (PO) |
|
Kokeellinen: Part 1 Dose Escalation Cohort 1B
Combination (PF-08165784 + fulvestrant) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug |
Selective Estrogen Receptor Degrader (SERD)
Muut nimet:
Taken by mouth (PO) |
|
Kokeellinen: Part 1 Dose Escalation Cohort 1C
Combination (PF-08165784 + fulvestrant + atirmociclib) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug |
Selective Estrogen Receptor Degrader (SERD)
Muut nimet:
Taken by mouth (PO) Selective CDK4 inhibitor
Muut nimet:
|
|
Kokeellinen: Part 1 Dose Escalation Cohort 1D
Combination (PF-08165784 + cetuximab) dose escalation for participants with advanced or metastatic CRC at different doses of the study drug |
Monoclonal antibody (EGFR inhibitor)
Muut nimet:
Taken by mouth (PO) |
|
Kokeellinen: Part 2 Dose Optimization/Expansion Cohort 2A
Combination (PF-08165784 + letrozole + atirmociclib) dose optimization/expansion for participants with advanced or metastatic BC, at different doses of the study drug |
Taken by mouth (PO) Selective CDK4 inhibitor
Muut nimet:
Nonsteroidal aromatase inhibitor
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)
Aikaikkuna: Baseline up to 28 days
|
Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes. |
Baseline up to 28 days
|
|
Part 1 (Dose Escalation): Number of participants with laboratory abnormalities
Aikaikkuna: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
Number of participants with laboratory test abnormalities. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)
Aikaikkuna: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 2 (Dose Expansion): Objective Response Rate (ORR)
Aikaikkuna: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Part 2 (Dose Expansion): Number of participants with laboratory abnormalities
Aikaikkuna: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
Number of participants with laboratory test abnormalities. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 2 (Dose Expansion): Incidence of Adverse Events (AEs)
Aikaikkuna: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 1 & Part 2: Disease Control Rate (DCR) as per RECIST v1.1
Aikaikkuna: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
DCR is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) per RECIST version 1.1. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Clinical Benefit Rate (CBR) as per RECIST v1.1
Aikaikkuna: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
CBR is defined as the percentage of participants with a best overall response of CR or PR at any time before Progressive Disease (PD), or non-CR/non-PD or SD for at least 24 weeks from start date of treatment and prior to PD, relative to the appropriate analysis set. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Duration of Response (DOR) as per RECIST v1.1
Aikaikkuna: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
DOR is defined as the time from first documentation of CR or PR to date of first documentation of PD or death due to any cause. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Progression-Free Survival (PFS) as per RECIST v1.1
Aikaikkuna: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Time to Response (TTR) as per RECIST v1.1
Aikaikkuna: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
TTR is defined as the time from start date of treatment to first documentation of CR or PR. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 2: Overall Survival (OS)
Aikaikkuna: Up to approximately 2 years
|
OS is defined as time from from start date of treatment to the date of death due to any cause |
Up to approximately 2 years
|
|
Part 1: Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Aikaikkuna: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
ORR is defined as the percentage of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1: Maximum Observed Serum Concentration (Cmax) & Trough Concentration (Ctrough)
Aikaikkuna: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Time to Reach Maximum Observed Serum Concentration (Tmax)
Aikaikkuna: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)
Aikaikkuna: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Effect of Food on Cmax
Aikaikkuna: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the effect of food on Cmax of PF-08165784 as monotherapy |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Effect of Food on Tmax
Aikaikkuna: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the effect of food on Tmax of PF-08165784 as monotherapy |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Effect of Food on AUClast
Aikaikkuna: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the effect of food on AUClast of PF-08165784 as monotherapy |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 2 (Dose Expansion): Pre- and post-dose concentrations of PF-08165784
Aikaikkuna: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the pre- and post-dose concentrations of PF-08165784 |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Pfizer CT.gov Call Center, Pfizer
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat sivustoittain
- Neoplasmat
- Suoliston sairaudet
- Neoplasmat histologisen tyypin mukaan
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan sairaudet
- Ruoansulatuskanavan sairaudet
- Kolorektaaliset kasvaimet
- Suoliston kasvaimet
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Paksusuolen sairaudet
- Ihosairaudet
- Rintojen sairaudet
- Iho- ja sidekudostaudit
- Karsinooma
- Paksusuolen kasvaimet
- Rintojen kasvaimet
- Hormonit
- Hormonit, hormonikorvikkeet ja hormoniantagonistit
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Orgaaniset kemikaalit
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Atsolit
- Polisykliset yhdisteet
- Vasta -aineet, monoklonaalinen, humanisoitu
- Vasta -aineet, monoklonaalinen
- Vasta -aineet
- Immunoglobuliinit
- Immunoproteiinit
- Veriproteiinit
- Seerumin globuliinit
- Globuliinit
- Steroidit
- Sulatettu rengasyhdisteet
- Nitriilit
- Estradioli
- Esreenit
- Estaanit
- Estradioli -yhdistäjät
- Gonadal -steroidihormonit
- Gonadal -hormonit
- Triatsolit
- Letrotsoli
- Fulvestrantti
- Setuksimabi
Muut tutkimustunnusnumerot
- C6631001
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .